Oncology Brothers @OncBrothers Twitter profile

Pinned Tweet

Oncology Brothers

7 days

Breast Ca Highlights from #ESMO24 w/ @PTarantinoMD - #NATALEE - #KN522 - #DestinyBreast12 Full Int: - - - Also on the “Oncology Brothers” podcast #bcsm #OncTwitter #MedTwitter @TargetedOnc @myESMO

2

5

24

Last Seen Profiles

@daddyisaac90

@Khaledmoneim2

@franklinveaux

@ANavarro_MD

@RadikLoveE46

@bokeplokalmalam

@Hiyoshisayasaya

@_sujitha_1

@Ke5iraM

@DasVicto

@naginogi23

@m_e1222_gu

@sn4k3maniac

@benmatsu1850

@Rodon_J

@jonculshaw

@Nat_087

@11numara1907

@urasawa_naoki

@3QACIWa5qhyC65

@pandulu

@Lisora_

@Anti_Neolibe

@pr_cny

@Stanford_AD

@SoaRGaming

@abd33

@PeachyTeaFGC

@shamsuddin_III

@AvahV37261

@UofMCOMM

@softbbybri

@cryptosbuddha

@anishsuliman666

@Purrloin

@melaniecot32610

Oncology Brothers

@OncBrothers

1 year

Day 1 #ASCO23 Highlights: 1. #NATALEE : Adj #ribociclib HR+ breast Ca 2. MONARCHE: Adj #abemaciclib update 3. #ATTRACTION5 : Adj Gastric Ca 4. #IMbrave050 : Adj HCC 5. OFS in Premenopausal 6. #IMerge imetelstat MDS @ASCO @OncoAlert #bcsm #gism #OncTwitter #MedTwitter 1/7

11

158

502

Oncology Brothers

@OncBrothers

2 years

#ASCO22 #PlenarySession summary 1. #DESTINYBreast04 : TDXd in low HER2 mBC 2. #PARADIGM : Pan + mFOLFOX6 vs Bev + mFOLFOX6 in mCRC 3. #rEECur : Topotecan, cyclophos & HD ifos in Ewing #Sarcoma 4. #DETERMINATION : RVd +/- ASCT + Rev in myeloma #BCSM #CRCSM #GISM #MMSM @OncoAlert 1/5

3

138

383

Oncology Brothers

@OncBrothers

3 years

8 new drugs/indications were approved by @FDAOncology for Thoracic Malignancies in 2021! We have created tables for indications and their results to stay organized and for a quick reference. #MedTwitter @OncoAlert #OncTwitter #LCSM @IASLC #lungcancer #thyroidcancer

4

118

369

Oncology Brothers

@OncBrothers

3 years

In 2021, 5 new drugs/indications were approved for GI malignancies by @FDAOncology : - Ivosidenib - Nivo in adj settings - Nivo + chemo - Pembro + chemo - TDxd Here is a summary! #GastricCancer #MedEd @OncoAlert @ASCO #GIOncology #CRCSM #MedTwitter #OncTwitter #Oncology

4

131

355

Oncology Brothers

@OncBrothers

1 year

< 3 weeks to #ESMO23 , here is a📝 of 🔑abstracts for general onc that could change our SoC! - #ALINA - #LIBRETTO431 - #TROPIONLung01 - #MARIPOSA - #Ev302 - #CM901 - #LITESPARK005 - #KN756 - #CABINET - #CODEBREAK300 #BCSM #GISM #LCSM #MedTwitter #GUSM #OncTwitter @myESMO

13

112

318

Oncology Brothers

@OncBrothers

1 year

Less than 2 weeks to #ASCO23 , here is our list of what we anticipate could be practice-changing/reinforcing! Please add if we left out that could change our practice post @ASCO @OncoAlert #bcsm #MedTwitter #OncTwitter #GISM #lcsm @TargetedOnc @TotalHealthConf @mydocwire #gusm

7

82

310

Oncology Brothers

@OncBrothers

2 years

We've been working on this table as each drug has its own approved IHC Assay & their own scoring method. Would love everyone to contribute to ensure its as comprehensive as possible #GISM #LCSM @HemOncFellows #BCSM @NarjustFlorezMD @JackWestMD @ADesaiMD #MedTwitter @MPishvaian

12

91

245

Oncology Brothers

@OncBrothers

4 months

Day 1 #ASCO24 Highlights: 1. #CROWN : Lorlatinib in ALK mNSCLC 2. #PALOMA3 : SC #Amivantamab in EGFR mNSCLS 3. #MARIPOSA : Ami in EGFR mNSCLC 4. #GlobalOncCoP @inas_md 5. #SocialMedia : Leveraging this @fumikochino @lungoncdoc #OncTwitter #MedEd #MedTwitter @ASCO #lcsm 1/6

2

90

237

Oncology Brothers

@OncBrothers

1 year

Day 1 #ESMO23 Highlights #CommunityOncology NSCLS 1. #CM816 @DrMarkAwad 2. #KN671 @DoctorJSpicer 3. #ATTLAS Breast Ca 4. #MonarchE #bcsm 5. #KN756 / #CM7FL @LoiSher 6. #KN522 TNBC @JavierCortesMD #lcsm #OncTwitter @myESMO #OncEd @OncoAlert @DrSGraff @g_mountzios 1/7

6

81

229

Oncology Brothers

@OncBrothers

1 year

Day 2 #ASCO23 Highlights: 1. #KN671 : PeriOp pembro in resectable NSCLC 2. #KN826 : Chemo + IO in cervical Ca 3. #DUOO : IO/PARPi ovarian cancer patients in 1L #lcsm @ASCO @OncoAlert #OncTwitter #MedTwitter #gyncsm 1/4

1

88

217

Oncology Brothers

@OncBrothers

2 years

Day 1 #ESMO22 Highlights #CommunityOncology 1. #MONARCH3 in mBC 2. #TROPiCS02 in mBC @hoperugo 3. Understanding HER-2Low Breast Ca @PTarantinoMD @prat_aleix 4. mTNBC in 2022 @DrLisaCarey 5. Management of RCC @ERPlimackMD @myESMO #MedTwitter #OncEd #bcsm #GUSM 1/6

3

66

212

Oncology Brothers

@OncBrothers

23 days

#WCLC24 Highlights #CommunityOncology : 1. #HARMONi2 in mNSCLC 2. #CM77TvsCM816 resectable NSCLC 3. #TROPIONLung01 in 2L mNSCLC 4. #SKIPPirr : AEs for Amivantamab 5. #TNM staging: 9th Ed 6. Personal highlights #lcsm #OncTwitter @IASLC 1/7

3

90

213

Oncology Brothers

@OncBrothers

1 year

#AACR23 highlights, what we need to know as a community onc: 1. #AEGEAN : Periop ChemoIO + AdjIO -NSCLC 2. #KN966 : Pembro/Gem/Cis -BiliaryCA 3. #IMbrave050 : Adj Atezo/Bev -HCC 4. #S1512 : Pembro-Desmoplastic #Melanoma #OncTwitter @OncoAlert #MedTwitter @AACR #lcsm #gism 1/5

3

77

207

Oncology Brothers

@OncBrothers

2 years

7 new drugs/indications were approved by @FDAOncology for lung cancer in 2022: - #Nivolumab in neoadj - #Capmatinib - #TDxD - #Selpercatinib - #Adagrasib - More IO options Here is a summary table: #MedTwitter @OncoAlert #OncTwitter #LCSM @IASLC #lungcancer #OncEd #MedEd

Oncology Brothers

@OncBrothers

3 years

8 new drugs/indications were approved by @FDAOncology for Thoracic Malignancies in 2021! We have created tables for indications and their results to stay organized and for a quick reference. #MedTwitter @OncoAlert #OncTwitter #LCSM @IASLC #lungcancer #thyroidcancer

4

118

369

4

59

210

Oncology Brothers

@OncBrothers

2 years

Day 2 #ASCO22 Highlights #CommunityOncology perspective 1. #DestinyBreast03 in mBC by @ErikaHamilton9 2. #PALOMA 2 update in mBC 3. #TROPICS2 in mBC by @hoperugo 4. #DYNAMIC : ctDNA guiding adjuvant Rx in CRC #MedEd #MedTwitter @OncoAlert @ASCO 1/5

3

72

205

Oncology Brothers

@OncBrothers

1 year

#WCLC23 Highlights #CommunityOncology 🔎: 1. #IMPower133 update ES-SCLC @StephenVLiu 2. #DESTINYLung02 Her2 NSCLC 3. #MARS2 : ✂️mesothelioma @ekslim 4. #FLAURA2 : 1L mEGFR 5. 2L mEGFR: #CHRYSALIS2 #HERTHENALung01 6. TNM 9thEd #lcsm @IASLC #OncTwitter #MedTwitter #MedEd

3

81

203

Oncology Brothers

@OncBrothers

3 years

. @FDAOncology has been busy to say the least. 7 new drugs/indications were approved for GU Malignancies in 2021! Here is a table summarizing those findings. #MedTwitter #OncTwitter #Oncology #bladdercancer #kidneycancer #MedEd @OncoAlert @ASCO @myESMO

7

88

198

Oncology Brothers

@OncBrothers

1 year

Our personal #ASCO23 highlights - seeing friends, mentors,mentees, and educators in person! Thank you, @ASCO ! A few common questions we got: - Are you really brothers? Yes. - Who’s older? The other brother! - How did it get started? As practicing general medical oncologists,

14

16

200

Oncology Brothers

@OncBrothers

11 months

What just happened? 5 new 💊/indications ✅ by @FDAOncology in the last 10 days. As #CommunityOncologists , we need to know them all: 1. #Fruquintinib in refractory mCRC, mPFS 3.7mos vs 1.8mos 2. #Pembrolizumab (+Chemo) in 1L mGEJ/Gastric Ca, mOS 12.9mos Vs 11.5mos

9

75

192

Oncology Brothers

@OncBrothers

2 years

< 2 weeks to #ESMO22 , here is a list of what we anticipate that could be critical for general oncologists s/p @myESMO Inspired by @DrChoueiri , @PTarantinoMD , @GillSharlene #BCSM #GISM #LCSM #OncEd #MedTwitter #GUSM @HemOncFellows @neerajaiims @CathyEngMD @FAndreMD @hoperugo

3

68

196

Oncology Brothers

@OncBrothers

2 years

2 weeks to #ASCO22 , here is a list of what we anticipate could be practice changing. Pls add if we left a critical abstract out that could change our treatment s/p @ASCO Inspired by @ErikaHamilton9 & @DrChoueiri @OncoAlert #BCSM #GISM #LCSM #OncEd #MedTwitter #Sarcoma #GUSM

5

74

195

Oncology Brothers

@OncBrothers

5 months

< 2 weeks to #ASCO24 , here is a📝 of 🔑abstracts for general onc that could guide our SoC! - #ESOPEC - #COMMIT - #INAVO120 - #DestinyBreast06 - #LAURA - #ADRIATIC - #NADINA - #MARIPOSA - #Amyloidosis #BCSM #GISM #LCSM #MedTwitter #GUSM #OncTwitter @ASCO @OncoAlert

6

78

196

Oncology Brothers

@OncBrothers

1 year

Day 4 #ASCO23 highlights 1. #TALAPRO2 : PARPi + Enza in mCRPC 2. #THOR : Erdafitinib in FGFR urothelial cancer 3. #VESPER : ddMVAC Vs Gem/Cis PeriOp MIBC 4. #CONTACT03 : Re-challenge IO in RCC @ASCO #OncTwitter #MedTwitter @OncoAlert #Gusm #KidneyCancer #BladderCancer 1/9

1

84

181

Oncology Brothers

@OncBrothers

3 years

Practical algorithm/landscape for treating patients with bladder cancer shared by @apolo_andrea during #OncoAlertColloquium and an updated algorithm by @EUplatinum . This should your SoC in the community! #OncEd #MedTwitter @OncoAlert

1

72

181

Oncology Brothers

@OncBrothers

2 years

Our 1000th tweet!!! #Oncology #OncologyBrothers @ASCO #Siblings Cannot thank #MedTwitter #OncTwitter & #HemeTwitter enough How it started How it's going

13

12

182

Oncology Brothers

@OncBrothers

1 year

#ESMO23 Day 3 Highlights #CommunityOnc : 1. #CABINET - NET 2. #GASTFOX - GEJ/mG 3. #JCOG1611 - PancCa #bladdercancer 4. #CM901 @apolo_andrea @MattGalsky 5. #EV302 HISTORY IN MAKING! “GOOSEBUMPS” as @DrChoueiri said! #gism #gusm #OncTwitter #MedTwitter @myESMO 1/6

2

65

176

Oncology Brothers

@OncBrothers

28 days

~1 week to #ESMO24 , here is a📝 of 🔑abstracts for general onc that could change/reinforce our SoC! - #NIAGARA - #KN522 - #NATALEE - #DB12 - #MARIPOSA2 - #KRYSTAL12 - #NICHE2 - #SAKK41 - #POD1UM - #KN811 #BCSM #GISM #LCSM #MedTwitter #GUSM #OncTwitter @myESMO @OncoAlert

0

60

177

Oncology Brothers

@OncBrothers

1 year

Day 3: #ASCO23 #Plenary summary 1. #INDIGO : Vorasidenib in Glioma 2. #PROSPECT : NeoAdj ChemoXRT or FOLFOX —> TME in Rectal Ca 3. #ADAURA : Adj #Osimertinib in NSCLC 4. @SWOG #S1826 : Nivo or Bv + AVD in advanced cHL #lcsm #lymsm #gism @ASCO #OncTwitter #MedTwitter @OncoAlert

2

79

175

Oncology Brothers

@OncBrothers

2 years

Day 1 #ASCO22 Highlights #CommunityOncology perspective 1. Pooled analysis for mNSCLC, ICI Vs. chemo + ICI by @FDAOncology 2. Outcomes of 1L KRASm NSCLC 3. #ECHELON1 update 4. Launch of ASCO Med CoP 5. #SHINE - 1L MCL #LCSM #MedEd #MedTwitter #LymSM @OncoAlert 1/6

1

45

169

Oncology Brothers

@OncBrothers

2 years

Day 1 #GI23 Highlights #CommunityOncology 1. #NeoAGIS : Chemo vs CROSS 2. #Infinity : NeoAdj IO dMMR G/GEJ Ca 3. #SPOTLIGHT : CLDN18.2 (Importance of NGS)- New SoC 4. #INTEGRATEIIA : Rego in pretreated pts @ASCO #OncEd #MedEd #Oncology @OncoAlert @HemOncFellows #gism

3

52

168

Oncology Brothers

@OncBrothers

3 months

#LungSeries : This is the #Algorithm we have used during our discussion w/ @DrSteveMartin for mNSCLC w/ actionable mutations in 1L: - EGFR, ALK, ROS1, BRAF, NTRK, MET Econ 14, RET!!! #OncTwitter #MedTwtitter @CancerNetwrk #lcsm

Oncology Brothers

@OncBrothers

3 months

#LungSeries : w/ @DrSteveMartin we 🗣️ the SoC for mNSCLC w/🎯mutation in 1L (Osi, Ami, Alectinib, Lorlatinib, et al) Full discussion: - - - Also on the “Oncology Brothers” podcast @CancerNetwrk #lcsm #OncTwitter #MedTwitter

4

29

7

53

161

Oncology Brothers

@OncBrothers

4 months

Day 2 #ASCO24 highlights: 1. #INAVO120 : Inavolesib mPIK3CA HR+ LA/mBC 2. #postMONARCH : Abema + Fulvestrant after CDK4/6i in mBC 3. #EMERALD : Eribulin + HP HER2 mBC 4. Favorable/V Favorable mRCC 5. #DREAMM7 : BVd 2L Myeloma #bcsm #lcsm #mmsm #OncTwitter @ASCO 1/10

1

60

162

Oncology Brothers

@OncBrothers

4 months

#ASCO24 Day 3: 1. #DB06 TDxD HR+ mBC 2. #TransMet Liver transplant mCRC 3. #Collision Surgery/Ablation mCRC 4. #ESOPEC UpperGI 5. #LAURA Consolidation mNSCLC 6. #ADRIATIC Durva LS-SCLC 7. #ReachPC : #PallOnc 8. #NADINA Melanoma #OncTwitter @OncoAlert #bcsm #lcsm 1/9

4

62

158

Oncology Brothers

@OncBrothers

1 year

#ESMO23 Day 4 Highlights #CommunityOnc : 1. #CAIRO5 - mColorectal Ca 2. #TROPIONBreast01 - HR+ #BreastCancer 3. #PSMAfore - mCRPC #ProstateCancer #LungCancer 4. #TROPIONLung01 5. #MARIPOSA 6. #MARIPOSA2 #gism #lcsm #bcsm #crcsm #OncTwitter @myESMO #Medtwitter 1/7

1

54

152

Oncology Brothers

@OncBrothers

9 months

Yet another busy year for @FDAOncology @US_FDA . ≥40 new approvals/indications in 2023 for Heme-Onc. Our end of year wrap-up tradition. Indications & study findings for the 5 approved 💊 in #LungCancer : #lcsm #MedTwitter #OncTwitter @VivekSubbiah #precisionmedicine #ret #braf

2

55

147

Oncology Brothers

@OncBrothers

2 years

Day 3 #GI23 Highlights #CommunityOncology 1. #MOUNTAINEER : Tucat+Trast approved CRC 2. #SUNLIGHT : TAS102+Bev confirmed late option CRC 3. #E2211 : Cape+Tem in pNET manuscript 4. #ctDNA kinetics CRC 5. TNT state in RectalCA @ASCO #OncEd #MedEd @OncoAlert #GISM #MedTwitter

2

61

147

Oncology Brothers

@OncBrothers

2 years

3 @FDAOncology approvals in less than 24 hours: 1. #Pembrolizumab adj NSCLC 2. #Pirtobrutinib refractory Mantle cell lymphoma 3. #Elacestrant HR+ mESR1 advanced breast CA #CommunityOncology @OncoAlert @HemOncFellows @US_FDA #MedTwitter #OncEd #MedEd

Oncology (Cancer) / Hematologic Malignancies Approval Notifications

FDA does not issue approval announcements for every approval or drug label update that occurs in oncology and hematology.

www.fda.gov

3

36

147

Oncology Brothers

@OncBrothers

8 months

This is the #algorithm we have used during our discussion for #HR positive #breastcancer w/ @VKaklamani #bcsm #onctwitter #meded #OncEd #MedTwitter #Oncology @CancerNetwrk

Oncology Brothers

@OncBrothers

8 months

#BreastCancer algorithm series, w/ @VKaklamani to reiterate the current SoC for HR+ Breast Cancer: Full Discussion: - - - Also on the “Oncology Brothers” podcast #bcsm #OncEd #OncTwitter #MedEd @CancerNetwrk #MedTwitter

1

16

37

4

53

145

Oncology Brothers

@OncBrothers

6 months

This is the updated #Algorithm for #BladderCancer . Nivo/Gem/Cis was not approved at the time of this discussion w/ @DrKarineTawagi and @siadaneshmand but has been incorporated in this is mage below. #OncTwitter #MedTwtitter #gusm #MedEd @CancerNetwrk #OncEd

Oncology Brothers

@OncBrothers

7 months

#BladderCancer algorithm, w/ @DrKarineTawagi & @siadaneshmand to reiterate the current SoC for this disease: Full Discussion: - - - Also on the “Oncology Brothers” podcast #OncTwitter #MedEd #gusm @CancerNetwrk #MedTwitter

0

7

36

4

63

140

Oncology Brothers

@OncBrothers

7 months

This is the #ProstateCancer algorithm we have used during our discussion with @DrRanaMcKay #MedEd #OncEd #OncTwitter #MedTwitter #gusm @CancerNetwrk

Oncology Brothers

@OncBrothers

7 months

#ProstateCancer algorithm, w/ @DrRanaMcKay to reiterate the current SoC for this disease: Full Discussion: - - - Also on the “Oncology Brothers” podcast #OncEd #OncTwitter #MedEd #gusm @CancerNetwrk #MedTwitter

1

9

32

2

42

143

Oncology Brothers

@OncBrothers

6 months

#TDxD now @US_FDA approved for pan-tumor w/ HER2 IHC3+ solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options. Based on DESTINY-PanTumor02, DESTINY-Lung01, and DESTINY-CRC02: - Dose 5.4 mg/kg - Common AE: fatigue,

4

54

140

Oncology Brothers

@OncBrothers

9 months

Summary of 10 new indications/approvals in Heme Malignancies (excluding CART) by @FDAOncology in 2023: 1. #Zanubrutinib 2. #Pirtobrutinib 3. #Polatuzumab 4. #Epcortimab 5. #Glofitamab 6. #Quizartinib 7. #Talquetamab 8. #Elranatamab 9. #Ivosidenib #HemeTwitter #MedTwitter

4

56

140

Oncology Brothers

@OncBrothers

3 years

As we get ready for Day 3 #GI22 , here is an algorithm that was shared for metastatic colorectal cancer from #CommunityOnc ’s perspective. Please recommend any updates/changes. #CRC #crcsm #OncED #MedTwitter @NCCN @OncoAlert #oncology

3

55

137

Oncology Brothers

@OncBrothers

2 months

#Melanoma : This is the #algorithm we have used during our discussion w/ @DrBetofMDPhD to cover the current landscape/SoC in cutaneous melanoma. #OncTwitter @CancerNetwrk #MedTwitter #OncEd

Oncology Brothers

@OncBrothers

2 months

#Melanoma : w/ @DrBetofMDPhD we 🗣️ the SoC for early, locally adv, & met melanoma! ✅ IO/BRAF-MEKi/Anti-Lag3 ✅ NADINA ✅ TILs Full discussion: - - - Also on the “Oncology Brothers” podcast @CancerNetwrk #OncTwitter #OncEd

1

10

31

2

52

136

Oncology Brothers

@OncBrothers

1 year

This is the updated #algorithm we used during our discussion w/ @DrGattiMays for HR+ #BreastCancer #sacituzumab (or is it “sassy toucan”) #elacestrant #TDxD #ERPositive #bcsm #OncTwitter #OncEd #MedTwitter @OncoAlert

Oncology Brothers

@OncBrothers

1 year

w/ @DrGattiMays , we 🗣 the Rx algorithm for HR+ breast ca and the recent approvals. Full Int: - - Also on “Oncology Brothers” 🎙 @PTarantinoMD @JAMouabbi and @DrGattiMays 🙏🏽 for this #breastcancer series! #bcsm #MedTwitter #OncTwitter #OncEd #MedEd

0

22

53

5

51

134

Oncology Brothers

@OncBrothers

4 months

#ASCO24 Day 4 Highlights: 1. #ICTAN : Adj anti-EGFR duration in NSCLC 2. #EV302 : Ev + Pembro HRQoL update in #bladdercancer 3. #CM901 Update in #bladdercancer 4. #ABRAVE in TNBC #OncTwitter #MedTwitter @ASCO @OncoAlert 1/5

2

53

135

Oncology Brothers

@OncBrothers

9 months

Summary of 5 new drugs/indications in GI malignancies that were @FDAOncology @US_FDA approved in 2023: - #Tucatinib - Mountaineer - #TAS102 + #Bevacizumab - Sunlight - #Pembro + Cis/Gem - KN966 - #Fruquintinib - FRESCO2 - #Pembro + Chemo - KN859 #OncTwitter #gism #crcsm

Oncology Brothers

@OncBrothers

2 years

Summary of the 4 new drugs/indications that were approved for GI malignancies by @FDAOncology in 2022: - Nivo & Ipi/Nivo - Durvalumab - Futibatinib - Treme + Durva #GastricCancer #MedEd @OncoAlert @ASCO #GIOncology #CRCSM #MedTwitter #OncTwitter #Oncology #gism

1

45

118

2

53

129

Oncology Brothers

@OncBrothers

3 years

3 new drugs/indications were approved by @FDAOncology for Breast Cancer in 2021. Here is a summary! #BCSM Thank you @ErikaHamilton9 @hoperugo @stolaney1 @DrHBurstein @DrNeilLove @PeerView @OncLive for discussions/guidance on how to apply these indications in our practice

1

49

133

Oncology Brothers

@OncBrothers

3 years

Day 1 #GU22 #prostateday @asco Summary (what we need to know for our clinics in the community tomorrow): 1. #ARASENS 2. #PROpel 3. #MAGNITUDE 4. #PRESIDE #practicechanging #prostatecancer #MedTwitter #OncEd @OncoAlert 1/5

3

56

131

Oncology Brothers

@OncBrothers

2 years

#Durvalumab @US_FDA approved for advanced biliary tract cancer #TOPAZ1 Ph3, 1L Durva + Gem/Cis vs. Gem/Cis - New SoC - OS (HR: 0.80) and PFS (HR0.75) with addition of Durva - Benefit seen regardless of PDL1. 2yr OS: 24.9% Vs 10.4% #GISM @OncoAlert @pashtoonkasi #MedTwitter

8

36

128

Oncology Brothers

@OncBrothers

10 months

#SABCS23 Day 2 Highlights #CommunityOnc : HR+ 1. Update #CM7FL + #KN756 2. #MONARCH3 3. #HER2CLIMB02 (Her2+) 4. Role of Anthracyclines 5. #OLAnzaPiNE (all solid tumors) 1/6 #bcsm #OncTwitter @SABCSSanAntonio @AACR @UTHealthSAMDA #BreastCancer #MedTwitter @ThanksCancer

3

50

118

Oncology Brothers

@OncBrothers

18 days

Day 3 #ESMO24 highlights: 1. #KN522 : Update TNBC 2. #NIAGARA : resectable MIBC @tompowles1 @PGrivasMDPhD 3. #CONTACT02 : Update mCRPC @neerajaiims 4. #NICHE2 : dMMR Colon Ca @MyriamChalabi 1/5 #OncTwitter @myESMO @OncoAlert #bcsm #gism #MedTwitter

1

47

128

Oncology Brothers

@OncBrothers

10 months

< 72 hrs to #SABCS23 , here is a📝 of 🔑abstracts from #CommunityOncologists perspective. 🙏🏽🙏🏽🙏🏽 @SABCSSanAntonio @AACR for selecting us to serve as SABCS 2023 Social Media Supporter! Stay tuned for EOD highlights! #MedEd #bcsm #OncTwitter @UTHealthSAMDA #breastcancer

5

41

126

Oncology Brothers

@OncBrothers

9 months

Day 1 #GI24 @ASCO Highlights #CommunityOncology 1. #KN590 update 2. #Docetaxel + FOLFOX in 1L GEJ/gastric AdenoCa 3. PeriOp IO in: - GEJ/Gastric ( #MATTERHORN ) - LA-ESCC ( #ESCORTNEO ) 4. #SKYSCRAPER08 (anti-TIGIT) in mESCC #OncEd #MedEd #OncTwitter #MedTwitter #gism 1/6

1

49

124

Oncology Brothers

@OncBrothers

10 months

#ASH23 Highlights #CommunityOnc : #Myeloma 1. #PERSEUS 2. #IsKia 3. #Bortezomib dosing CLL Update 4. #SEQUOIA & #ALPINE cHL Update 5. #SWOGS1826 MF 6. #TRANSFORM1 & #MANIFEST2 1/7 #HemeTwitter #OncTwitter #MedEd #AMLsm #MMsm #MDSsm @ASH_hematology @SWOG

5

49

122

Oncology Brothers

@OncBrothers

3 years

Neoadj Nivolumab + Chemo now @FDAOncology approved for NSCLC. #CM816 : Ph3, N= 358, Neoadjuvant, Nivo + Chemo Vs Chemo alone, resectable IB-IIIA NSCLC - pCR of 24% vs 2% with Nivo - improved EFS @OncoAlert #LCSM @ASCO #MedTwitter #OncEd

3

45

121

Oncology Brothers

@OncBrothers

2 years

3 new drugs/indications were approved by @FDAOncology for Breast Cancer and 2 for Gyn Onc in 2022. Here is a summary! - #TDXd x 2 - #Olaparib - #Pembrolizumab - #Mirvetuximab #bcsm #gynsm @OncoAlert #breastcancer #MedTwitter #OncEd #MedEd #ovariancancer

0

40

121

Oncology Brothers

@OncBrothers

2 years

Summary of the 4 new drugs/indications that were approved for GI malignancies by @FDAOncology in 2022: - Nivo & Ipi/Nivo - Durvalumab - Futibatinib - Treme + Durva #GastricCancer #MedEd @OncoAlert @ASCO #GIOncology #CRCSM #MedTwitter #OncTwitter #Oncology #gism

Oncology Brothers

@OncBrothers

3 years

In 2021, 5 new drugs/indications were approved for GI malignancies by @FDAOncology : - Ivosidenib - Nivo in adj settings - Nivo + chemo - Pembro + chemo - TDxd Here is a summary! #GastricCancer #MedEd @OncoAlert @ASCO #GIOncology #CRCSM #MedTwitter #OncTwitter #Oncology

4

131

355

1

45

118

Oncology Brothers

@OncBrothers

1 year

#Talazoparib + Enza now @FDAOncology approved 1L, mCRPC HRR deficient #TALAPRO2 : - Improved rPFS in all comers (HR 0.45) - rPFS was higher in BRCA 1/2 - OS immature, but 📈 towards survival Congratulations @neerajaiims et Al. #gusm @OncoAlert #OncTwitter #MedTwitter #brca

3

47

119

Oncology Brothers

@OncBrothers

2 months

#LungSeries : This is the #Algorithm we have used during our discussion with @FordePatrick for early + locally advanced NSCLC: awaiting approval for AEGEAN, CM77T, and LAURA! #lcsm #OncTwitter #MedTwitter @OncoAlert @CancerNetwrk

Oncology Brothers

@OncBrothers

2 months

#LungSeries : w/ @FordePatrick we 🗣️ the SoC for early + locally adv NSCLC. How much benefit do we get from PostOp IO? Full discussion: - - - Also on the “Oncology Brothers” podcast @CancerNetwrk #lcsm #OncTwitter #MedTwitter

1

7

29

5

31

118

Oncology Brothers

@OncBrothers

1 year

#ESMO23 Day2 ⚡️🔥 #CommunityOncology 1. DB04 ⬇️Her2 #bcsm #NSCLC 2. #ALINA ALK+ @bensolomon1 3. #LIBRETTO431 RET+ 4. #PAPILLON Exon20 5. #CM77T ✂️ 6. #LITESPARK005 Belzutifan-RCC @DrChoueiri 7. #SPOTLIGHT Cldn18.2 #gism #OncTwitter #MedTwitter @myESMO #lcsm 1/8

2

54

118

Oncology Brothers

@OncBrothers

1 year

This is the algorithm we used during our discussion with @CathyEngMD to go over the current landscape of #ColonCancer #crcsm #GITwitter #MedEd @OncoAlert @OncoJurdi #OncTwitter #MedTwitter @pashtoonkasi @SKamath_MD @GIcancerDoc @TumorBoardTues

Oncology Brothers

@OncBrothers

1 year

w/ @CathyEngMD , we 🗣 the Rx algorithm for #ColonCancer and the pending #Fruquintinib approval. Full Int: - - Also on the “Oncology Brothers” podcast 🎙️ @OncoAlert @GIcancerDoc #gism @HemOncFellows @VUMCHemOnc #crcsm #OncTwitter #MedTwitter #OncEd

0

16

68

6

41

115

Oncology Brothers

@OncBrothers

5 months

This is the #Algorithm we have used during our discussion w/ @KlempnerSam for #UpperGI - Testing for MSI, Her 2, CPS (and soon Cldn18.2) is critical! #OncTwitter #MedTwtitter #gism #MedEd @CancerNetwrk #OncEd

Oncology Brothers

@OncBrothers

5 months

GI Series: #UpperGi algorithm, w/ @KlempnerSam to reiterate the current landscape: Full Discussion: - - - Also on the “Oncology Brothers” podcast #OncTwitter @CancerNetwrk #MedTwitter #GISM

2

16

46

2

38

116

Oncology Brothers

@OncBrothers

2 years

Day 1 #GU23 #ProstateCacer Highlights #CommunityOncology 1. #TALAPRO2 : mCRPC PARPi 1L @neerajaiims 2. #TRITON3 : mCRPC PARPi 2L @AlanBryce9 3. #ARASENS update Dara+Doce 1L 4. #PROPEL update PARPi 1L @ASCO #OncEd #MedEd @OncoAlert #GUSM #MedTwitter

1

42

117

Oncology Brothers

@OncBrothers

20 days

Day 1 #ESMO24 Highlights #CommunityOncology 1. #TiNivo2 ≥2L mRCC @DrChoueiri 2. #LITESPARK005 : 2L mRCC @brian_rini 3. #DB12 : Her2+ brain Mets Breast Ca @nlinmd 4. #ADRIATIC : LS-SCLC 5. #PandasProdige44 : Panc Ca 1/6 #lcsm #OncTwitter @myESMO @OncoAlert #gism #bcsm

1

52

116

Oncology Brothers

@OncBrothers

6 months

This is the #Algorithm we have used during our discussion w/ @GIcancerDoc for #HCC ! #OncTwitter #MedTwtitter #gism #MedEd @CancerNetwrk #OncEd #LiverCancer

Oncology Brothers

@OncBrothers

6 months

GI Series: #HCC algorithm, w/ @GIcancerDoc to reiterate the current landscape: Full Discussion: - - -Also on the “Oncology Brothers” podcast -🗣️ @aparna1024 & @KlempnerSam to follow. #OncTwitter @CancerNetwrk #MedTwitter #GISM

0

8

33

6

38

114

Oncology Brothers

@OncBrothers

3 years

Roadmap for Early TNBC and for Metastatic TNBC by @hoperugo (thanks @ErikaHamilton9 and @DrSGraff for sharing). Amazing summary/algorithms that we can easily follow in our community settings #SABCS21 #bcsm

1

46

114

Oncology Brothers

@OncBrothers

1 year

Why is General/Community Oncology the best job? We get to celebrate every win in this field + share the data and present these Rx options to our pts! Wow @myESMO !! Be it mUC (EV/Pembro) or ALK+ NSCLC Adj Alectinib (or TDXD from #ASCO22 ). Whenever either of us (brothers) talk to

3

18

114

Oncology Brothers

@OncBrothers

10 months

#SABCS23 Day 4 Highlights #CommunityOnc : 1. #NATALEE update 2. #INAVO120 3. #KN522 update 4. #KATHERINE update 5. Summary by @IlanaSchlam 1/5 #bcsm #OncTwitter @SABCSSanAntonio @AACR @UTHealthSAMDA #BreastCancer #MedTwitter #OncEd #Oncology @VKaklamani

4

45

112

Oncology Brothers

@OncBrothers

19 days

Day 2 #ESMO24 highlights: 1. #MARIPOSA2 NSCLS @DrSanjayPopat 2. #KRYSTAL12 NSCLC 3. #KN811 Her2+ G/GEJ Ca 4. #PEACE3 mCRPC @Silke_Gillessen 5. #Cachexia @DrR_DUNNE 6. #KNA18 Cervical Ca 7. #POD1UM303 Anal Ca 8. #LEAP012 HCC 1/9 #OncTwitter @myESMO @OncoAlert

2

54

112

Oncology Brothers

@OncBrothers

9 months

Day 2 #GI24 @ASCO Highlights #CommunityOncology 1. #IMbrave151 2. GI/ColoRectal Ca in young adults 3. #ALPACA 4. #EXTEND 5. #NETTER2 6. #EMERALD1 #OncEd #MedEd #OncTwitter #MedTwitter #gism #crcsm #pancsm 1/7

4

43

112

Oncology Brothers

@OncBrothers

2 years

Tumor agnostic approvals are becoming more common. 4 new drugs/indications were approved by @US_FDA @FDAOncology for mutation driven malignancies and 3 for skin/soft tissue cancers, here is a summary! #BRAF #RetFusion #PrecisionMedicine #MedTwitter #OncEd #MedEd @OncoAlert

1

41

111

Oncology Brothers

@OncBrothers

6 months

#Alectinib now @FDAOncology approved based off #ALINA trial. Alectinib vs Chemo post resection in NSCLC, Stg Ib-IIIA: - Alectinib for 2 yrs - Improved DFS in all subgroups: HR0.24 - Improved CNS DFS HR: 0.22 - New Soc @bensolomon1 #lcsm #onctwitter #medtwitter

1

42

110

Oncology Brothers

@OncBrothers

1 year

Breast Cancer Highlights from #ASCO23 w/ @DrSGraff - #NATALEE - #SONIA - X-7/7 Full Int: - - Also on “Oncology Brothers” podcast #bcsm @ASCO @PTarantinoMD #OncTwitter #MedTwitter @ErikaHamilton9 @DrGattiMays @DrLoveResearch @TargetedOnc #MedEd

1

53

108

Oncology Brothers

@OncBrothers

10 months

#SABCS23 Day 1 Highlights #CommunityOnc : @FDAOncology Review on recent approvals 1. #CAPItello291 2. #EMERALD 3. #TDxD 4. Tumor Agnostic landscape 5. Post CDK4/6i HR+ @SABCSSanAntonio @VivekSubbiah @VKaklamani @JaniceTNBCmets #bcsm @DrSGraff @oreganruth 1/6

2

42

109

Oncology Brothers

@OncBrothers

16 days

#Ribociclib now @US_FDA ✅ for adj early stage HR+ breast cancer. Recent #ESMO24 #NATALEE : Stg IIA - III, 400mg (3wks on/1wk off) for 3yrs - Improved iDFS w/Ribo at 4yrs (HR: 0.715) - Improvement seen in all subgroups including N0. OS immature #bcsm #OncTwitter @OncoAlert

Tatiana Prowell, MD

@tmprowell

16 days

📣 NEW #OncTwitter 🇺🇸 Ribociclib is now FDA-approved for treatment of adults with stage 2 & 3 hormone receptor positive, HER2 negative #breastcancer at high risk of recurrence based on efficacy & safety results of the NATALEE trial. #bcsm #regulatory #ESMO24

4

18

55

1

42

107

Oncology Brothers

@OncBrothers

11 months

#Fruquintinib is now @FDAOncology approved based #FRESCO2 in refractory mCRC (discussed this w/ @CathyEngMD previously, link👇). - mOS 7.4mos vs 4.8mos (HR=0.66) - ORR: 16% vs 1.5% - mPFS 3.7mos vs 1.8mos - New treatment option for our refractory mCRC Pts! #crcsm #OncTwitter

Oncology Brothers

@OncBrothers

1 year

w/ @CathyEngMD , we 🗣 the Rx algorithm for #ColonCancer and the pending #Fruquintinib approval. Full Int: - - Also on the “Oncology Brothers” podcast 🎙️ @OncoAlert @GIcancerDoc #gism @HemOncFellows @VUMCHemOnc #crcsm #OncTwitter #MedTwitter #OncEd

0

16

68

2

29

105

Oncology Brothers

@OncBrothers

2 years

Quarter 1, 2022 Oncology Earnings Report #PracticeChanging studies/approvals so far🧵 1. #LuPSMA approved for Prostate Cancer 2. #DESTINYBreast03 TDXd superior to TDM-1 2L Her2+ mBC 3. #Pembro approved for 2L MSI-H endometrial CA #OncTwitter #OncEd #MedTwitter @OncoAlert

5

54

105

Oncology Brothers

@OncBrothers

2 years

So much has changed in such a short time for HER2+ #breastcancer . To continue our series, @ErikaHamilton9 walks us through the algorithm to reiterate SoC in the community for HER2+ breast CA: - - #bcsm #MedTwitter #OncMedEd

5

22

102

Oncology Brothers

@OncBrothers

7 months

#Amivantamab now @FDAOncology approved for mNSCLC Exon20 based off #PAPPILON in 1L w/ chemo: - PFS 11.4mos w/Ami vs 6.7mos chemo (HR: 0.40) - ORR in 73% vs 47% - OS favoring Ami (HR: 0.67) - 7%⛔Ami because of AEs - New SoC/Practice Changing #lcsm #onctwitter #medtwitter

1

36

100

Oncology Brothers

@OncBrothers

17 days

Day 4 #ESMO24 highlights: 1. #NATALEE : Update Adj HR+ Breast Ca 2. #Zolbetuximab : Update Cldn18.2 mG/GEJ Adeno Ca 3. #CABINET : NET 4. #LAURA : Update mEGFR NSCLC 5. #AMBASSADOR : Update Adj Bladder Ca 1/6 #OncTwitter @myESMO @OncoAlert #bcsm #gism #MedTwitter

2

37

101

Oncology Brothers

@OncBrothers

8 months

This is the #algorithm we have used during our discussion for #TNBC w/ @oreganruth & @AnnaWeissMD #bcsm #OncTwitter #MedTwitter #OncEd #BreastCancer @CancerNetwrk

Oncology Brothers

@OncBrothers

8 months

#BreastCancer algorithm series, starting off w/ @oreganruth & @AnnaWeissMD to reiterate the current SoC for TNBC: Full Discussion: - - - Also on the “Oncology Brothers” podcast #bcsm #OncEd #OncTwitter #MedEd @CancerNetwrk

3

13

23

1

32

98

Oncology Brothers

@OncBrothers

2 months

Durva + Chemo now approved based off #AEGEAN : PeriOp Durva + NeoAdj Chemo -> ✂️ -> 1yr Durva, IIA-IIIB (N2) NSCLC. - PeriOp IO/Chemo improves pCR 17.2% Vs. 4.3% - Improved EFS (also seen in #CM816 ). HR: 0.68 - KN671, CM816, and now AEGEAN (awaiting CM77T) #lcsm #OncTwitter

2

44

98

Oncology Brothers

@OncBrothers

9 months

In 2023, 3 more drugs/indications were approved for #BreastCancer by @FDAOncology @US_FDA : - #Elacestrant in ESR1 HR+ - #Sacituzumab in endocrine resistant HR+ - #Capivasertib in AKT1/PIK3CA/PTEN mutation HR+ #bcsm #OncTwitter #MedTwitter #oncology @ThanksCancer

Oncology Brothers

@OncBrothers

2 years

3 new drugs/indications were approved by @FDAOncology for Breast Cancer and 2 for Gyn Onc in 2022. Here is a summary! - #TDXd x 2 - #Olaparib - #Pembrolizumab - #Mirvetuximab #bcsm #gynsm @OncoAlert #breastcancer #MedTwitter #OncEd #MedEd #ovariancancer

0

40

121

0

40

97

Oncology Brothers

@OncBrothers

1 year

#CM816 3yr update was recently presented at #ELCC23 (OS: 0.67 and EFS 57% at 3yrs/65% at 2yrs) and today, #AEGEAN data was presented at #AACR23 . How much is adjuvant durva adding here? Unfortunately, we are left with cross trial comparisons given study design. #lcsm

5

28

97

Oncology Brothers

@OncBrothers

2 years

#WCLC22 Highlights #CommunityOncology perspective: 1. #YESS Study - @RachM_UoN 2. #IMPower010 Update 3. #CALGB140503 - Sublobar resection 4. #SHAWL Study - @NarjustFlorezMD @jillfeldman4 5. #NADIM2 Trial by @MARIANOPROVENCI 1/6 #LCSM #MedTwitter @OncoAlert #OncEd @IASLC

2

46

97

Oncology Brothers

@OncBrothers

6 months

This is the #Algorithm we have used during our discussion w/ @aparna1024 on #ColonCancer - Clinical Trials should ALWAYS be on our radar! #OncTwitter #MedTwtitter #gism #MedEd @CancerNetwrk #OncEd #crcsm

Oncology Brothers

@OncBrothers

6 months

GI Series: #ColonCancer algorithm, w/ @aparna1024 to reiterate the current landscape: Full Discussion: - - -Also on the “Oncology Brothers” podcast #OncTwitter @CancerNetwrk #MedTwitter #GISM #crcsm

0

14

47

4

33

94

Oncology Brothers

@OncBrothers

8 months

This is the #algorithm we have used during our discussion for #Her2 positive #BreastCancer w/ @DrHBurstein #bcsm #OncTwitter #MedTwitter #OncEd #BreastCancer @CancerNetwrk

Oncology Brothers

@OncBrothers

8 months

#BreastCancer algorithm series, w/ @DrHBurstein to reiterate the current SoC for Her2+: Full Discussion: - - - Also on the “Oncology Brothers” podcast #bcsm #OncEd #OncTwitter #MedEd @CancerNetwrk #MedTwitter

3

8

28

3

29

92

Oncology Brothers

@OncBrothers

7 months

This is the #KidneyCancer algorithm we have used during our discussion with @montypal #MedEd #OncEd #OncTwitter #MedTwitter #gusm @CancerNetwrk

Oncology Brothers

@OncBrothers

7 months

#KidneyCancer algorithm, w/ @montypal to reiterate the current SoC for this disease: Full Discussion: - - - Also on the “Oncology Brothers” podcast #OncEd #OncTwitter #MedEd #gusm @CancerNetwrk #MedTwitter #RCC @cityofhope

2

10

32

1

28

91

Oncology Brothers

@OncBrothers

1 month

#MARIPOSA : Ph III, n= 1074, 1L Ami + lazertinib in EGFR mNSCLC - Ami + Laz now @FDAOncology approved in 1L - Improved PFS in ALL high risk features (HR: 0.49 to 0.71) from recent #ASCO24 #lcsm #onctwitter #MedTwitter

Jill Feldman

@jillfeldman4

1 month

Exciting news for the #EGFR #lungcancer community! The FDA has approved amivantanab + lazertinib as a first-line therapy for #EGFR #NSCLC ! This new option brings promising PFS benefits from the MARIPOSA study to more patients—something we’ve needed for far too long. Remember,

5

22

119

2

33

93

Oncology Brothers

@OncBrothers

2 months

🎉 It's been 3 yrs since we joined social media! We're so grateful for the support, learning, and all the help in doing better for our patients every day. Here's to many more years of bridging the gap between academia and community in oncology🙏🙏 🙏 #MedTwitter #OncTwitter

13

7

93

Oncology Brothers

@OncBrothers

8 months

Day 1 #GU24 @ASCO Highlights #CommunityOncology 1. #CONTAC02 : Atezo/Cabo mCRPC 2. #BRCAAWAY : PARPi in mCRPC 3. #EMBARK : High Risk biochemical recurrence #ProstateCancer cancer #OncEd #MedEd #OncTwitter #MedTwitter #gusm 1/4

2

34

88

Oncology Brothers

@OncBrothers

1 year

This is the #algorithm we had used during our discussion with @DrSapnaPatel to go over the current landscape of #melanoma We have incorporated the recent #Nivolumab approval in this algorithm for adjuvant Stg IIB/C #MedEd #Oncology #MedTwitter #OncTwitter #OncEd @OncoAlert

Oncology Brothers

@OncBrothers

1 year

w/ @DrSapnaPatel we🗣️SoC for #Melanoma & key📝 to focus on in the community: - Adj IO Vs BRAF-MEKi - Switch Rx - #CTLA4 Full discussion: - - Also on the “Oncology Brothers” podcast #MedTwitter #OncTwitter #OncEd #Oncology @CureMelanoma @SWOG

0

6

18

2

22

91

Oncology Brothers

@OncBrothers

8 days

#Osimertinib now @US_FDA approved based off #LAURA : Ph III, Indefinite Osimertinib after ChemoXRT in Stage III mEGFR NSCLC: New SoC - ⬆️PFS w/ Osi, 39.1mos vs 5.6mos (HR 0.16) - 2 yr PFS: 65% vs 13% - Improved CNS PFS - ≥Gr 3 AEs: 35% vs 12% #OncTwitter #lcsm #MedTwitter

Eric K. Singhi, MD

@lungoncdoc

8 days

‼️ @FDAOncology approves osimertinib for locally advanced, unresectable stage III NSCLC after chemoradiation. Phase 3 LAURA study ▫️EGFR exon 19 deletions or exon 21 L858R mutations ▫️osimertinib 80 mg daily ▫️⬆️ PFS v placebo (39.1 months v 5.6 months, HR 0.16) @OncoAlert

2

10

28

1

43

112

Oncology Brothers

@OncBrothers

11 months

#Capivasertib now @FDAOncology approved w/ AKT alteration based off: #CAPItello291 : Capi + Fulvestrant vs Fulvestrant + Placebo - ⬆️ PFS w/ capivasertib 7.2mos vs 3.6mos (HR 0.60) - Pending OS - 400mg BID, 4days on/3days off - Diarrhea a big SE #bcsm #MedTwitter #OncTwitter